Read More

Adverum Biotech Saturday Morning Highlighted Will Present Data From Its INFINITY Trial Of ADVM-022 In Patients With Diabetic Macular Edema During American Society of Retina Specialists Meeting Oct. 11 At 9:50 a.m. EDT

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today is presenting data from the INFINITY clinical trial of ADVM-022 in

ADVM